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Budd-Chiari syndrome is the generic term for different 
forms of hepatic venous outflow obstruction resulting in a 
clinical picture of portal hypertension and hepatomegaly. 
Three levels of venous outflow obstruction may be 
recognized, affecting respectively the small intrahepatic 
venules, the large hepatic veins and the inferior vena cava 
(IVC). Each level of obstruction is related to a different 
aetiology. Clinical manifestations range from mild 
symptoms to acute or chronic end-stage liver disease. 
Treatment is surgical in the great majority of patients. 
Occlusion of the IVC may be treated by removal of the 
caval obstruction in selected patients. Hepatic outflow 
obstruction may be circumvented by different forms of 
shunting from the portal or upper mesenteric vein to the 
IVC or right atrium, depending on the level of obstruction 
and the difference in venous pressure. For the rare patient 
presenting with acute or chronic end-stage liver failure, 
hepatic transplantation may be a life-saving procedure. 
The syndrome of portal hypertension with hepatomegaly 
due to hepatic venous outflow obstruction was first 
described by Buddl; the associated histology was first 
described by Chiari2 hence the name Budd-Chiari 
syndrome. The outflow obstruction, caused by occlusion 
of the smaller or larger hepatic veins or the inferior vena 
cava (IVC) between the liver and the right atrium, results 
in right-sided upper abdominal pain, hepatomegaly and 
(often) massive ascites. For this review the proposal of 
Ludwig et aL3 is adopted: Budd-Chiari syndrome consists 
of hepatic venous outflow obstruction and its 
manifestations, regardless of cause, the obstruction being 
either within the liver or in the IVC. Functional hepatic 
outflow obstruction caused by congestive heart failure is 
not considered to be Budd-Chiari syndrome. 
The syndrome may be specified by several character- 
istics; anatomical, aetiological and morphological. 
Although the diagnosis is quite straightforward, definitive 
treatment is often postponed until serious liver damage 
becomes apparent, and surgical intervention is associated 
with many complications. Several surgical procedures lay 
claim to superior results but, in this rare disease, it is 
difficult to choose the right form of hepatic venous 
decompression for an individual patient. This is especially 
so in the light of new treatment options such as liver 
transplantation and, more recently, transjugular 
intrahepatic portasystemic shunting. The aim of this 
review is twofold: to provide guidelines for diagnosis and 
therapy in general, and to describe an approach for the 
management of the individual patient. 
Aetiological considerations 
Traditionally, the level of hepatic venous occlusion in 
Budd-Chiari syndrome is differentiated into three groups: 
the small hepatic venules, the major hepatic veins and the 
IVC. 
The first description of occlusion of the small hepatic 
venules by Chiari2 used the term ‘obliterative 
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endophlebitis’; today this would be regarded as veno- 
occlusive disease. It may result from ingestion of 
hepatotoxins such as pyrrolizidine  alkaloid^^-^. Bras et al. 
described the disease in Jamaica and related it to the 
ingestion of ‘bush teas’, which contain pyrrolizidine 
alkaloids such as senecio and crotalaria. The same histo- 
pathological picture results from chemotherapy and 
radiotherapy regimens to prepare patients for bone 
marrow tran~plantation~,’~. It has also been described in 
relation to conventional chemotherapy and to 
azathioprine treatment after renal transplantation’l. 
Occlusion of the major hepatic veins is, in many 
instances, secondary to an underlying disease (detected or 
undetected). Three main causative states may be recog- 
nized: a hypercoagulable state, malignancy and a residual 
group of miscellaneous diseases. A hypercoagulable state 
may occur in the course of various myeloproliferative 
syndromes, paroxysmal nocturnal haemoglobinuria, 
circulating lupus coagulant, BehGet’s disease, and 
deficiencies of antithrombin 111, protein C and protein 
S12-19. The use of oral contraceptives is frequently listed 
under the factors predisposing to Budd-Chiari 
~yndrome*~-~~ .  In case-control studies, however, the risk 
of the syndrome from oral contraceptive use seems 
significant only in the presence of a thrombogenic 
tendency in patients with an underlying haematological 
disorder, which, at time of diagnosis of Budd-Chiari 
syndrome, may still be Increased 
thrombogenicity may play a role in eclampsia and in 
pregnancy as a cause of the syndrome, but why the major 
hepatic veins are the target vessels is ~ n c l e a r ~ ~ - ~ ~ .  Crohn’s 
disease and aspergillosis may cause Budd-Chiari 
syndrome but this is a n e ~ d o t a l ~ ~ , ~ ~ .  Hepatocellular 
carcinoma, cysts and abscesses within the liver, and 
tumours outside the liver (such as rhabdomyosarcoma, 
leiomyosarcoma and leiomyoma) may obstruct the hepatic 
veins, leading to the ~ y n d r o m e ~ ~ - ~ ~ .  
Occlusion of the IVC between the hepatic veins and the 
right atrium may be caused by a membrane, by 
thrombosis or by compression from o ~ t s i d e ~ ~ - ~ ~ .  The first 
description of a membranous web is attributed to Osler4’ 
in 1879. It is a rare cause for Budd-Chiari syndrome in 
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the Western world, but accounts for the majority of cases 
in oriental series and in South A f r i ~ a ~ I - ~ ~ ;  it is also noted 
with greater frequency in areas of the USA inhabited by 
oriental  immigrant^^^. There is increasing evidence that 
pre-existing cirrhosis and previous hepatitis predispose to 
a membranous obstruction and in affected patients an 
unusually high incidence of hepatitis B positivity is 
f o ~ n d ~ ~ - ~ ~ .  The nature of the web, acquired or congenital, 
is not completely clear, but membranous obstruction is 
extremely rare in ~ h i l d r e n ~ ~ , ~ ’ .  The high incidence of 
primary diseases in these patients supports the concept of 
a thrombotic lesion preceding the membranous obstruc- 
tion5’. This view is strengthened by the careful study of 
Kage and  colleague^^^, which favoured a thrombotic 
nature for the membrane after an analysis of 17 autopsy 
cases. 
Pathology 
The pathological picture is different in early and late 
Budd-Chiari syndrome. In the acute situation the liver 
may be extremely enlarged, macroscopically congested 
and (red-purple) discoloured with blunt edges. Histo- 
logical examination shows normal periportal areas in the 
early stages, but the perivenular liver tissue is darkened by 
blood congestion caused by the venous thrombosis. This 
Fig. 1 Thrombosis of central veins with pericentral blood 
congestion and atrophy of hepatocytes 
Fig. 2 Collapse of pericentral stromal tissue with bleeding and 
extensive death of hepatocytes. 
leads to atrophy and death of the centrolobular 
hepatocytes (Fig. 1). Following the collapse of stromal 
tissue, the central veins obliterate. The sinusoids become 
devoid of erythrocytes which are typically concentrated in 
the space of D i s ~ e ~ ~ .  Without adequate treatment the 
acute, and possibly reversible, situation becomes chronic 
and irreversible (Fig. 2). Fibrin thrombi organize as 
fibrous cores. Thin collagen strands replace the liver cords 
and the collapsed stroma, and regeneration occurs as the 
first sign of fibrosis and ~ i r r h o s i s ~ ~ .  As the caudate lobe 
drains directly into the IVC by small and often unaffected 
veins, this segment may compensate for the loss of 
functioning liver tissue, sometimes by impressive 
enlargement; it may take over the function of the other 
affected liver segments. 
Clinical manifestations 
The onset of symptoms is often insidious with vague 
upper abdominal discomfort and progressive ascites 
caused by portal h y p e r t e n ~ i o n ~ ~ , ~ ~ .  Mild jaundice may be 
present with minimal liver dysfunction at first 
presentation. At this early stage Budd-Chiari syndrome 
may mimic constrictive per i~ardi t is~~.  Physical findings 
that suggest vena caval occlusion include leg oedema, 
episodes of pulmonary embolism and, sometimes, 
impressive varicose veins of legs, abdomen and lumbar 
r e g i ~ n ~ ~ , ~ ~ .  Some patients with IVC occlusion, however, 
have no symptoms at all6’. With diuretic therapy, the 
clinical picture may appear reassuringly improved, but 
such treatment is only symptomatic and increasing portal 
hypertension leads to oesophageal variceal haemorrhage 
and progressive liver failure61. In a small proportion of 
cases, Budd-Chiari syndrome first presents as fulminant 
hepatic failure; within 8 weeks of onset encephalopathy, 
coagulopathy and massive hepatic necrosis may O C C U ~ ~ ’ , ~ ~ .  
Bismuth and Sher10ck~~ have proposed a classification for 
these different clinical manifestations of the syndrome 
according to the degree of concomitant liver failure: 
fulminant, acute, subacute and chronic. 
Investigations 
Ultrasonography is today the first and most important tool 
in the diagnosis of Budd-Chiari syndrome, with a sensi- 
tivity of over 85 per cent65,66. The absence of major 
hepatic vein images and the classical enlargement of the 
caudate lobe may be demonstrated by this techr~ique~~*~*.  
With duplex scanning the portal and hepatic venous flow, 
as well as flow in the IVC, can be m e a ~ u r e d ~ ~ - ~ ’  and 
these correlate well with ven~graphy~~ .  Magnetic 
resonance imaging is capable of providing static and 
functional information about the hepatic veins and the 
IVC, but its additional value remains to be a ~ s e s s e d ~ ~ - ~ ~ .  
Parenchymal abnormalities are best demonstrated by 
computed tomography, as shown in a comparative study 
by Miller and co l l eag~es~~ .  Necrotic masses or nodular 
regenerative hyperplasia may resemble metastases, which 
should be excluded by fine-needle aspiration ~ y t o l o g y ~ ~ - ~ ~ .  
Radiocolloid scintigraphy of the liver, typically showing an 
increase of isotope centrally in the organ and hypertrophy 
of the caudate lobe, is today of only historical interests6.82. 
Angiographic catheterization of the IVC and hepatic 
veins may show occlusion or a narrowing of the vena cava 
due to compression by the caudate lobes3. If the hepatic 
veins can be visualized, a typical intrahepatic ‘spider’s 
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web' may be seens6,x3. Intraluminal IVC pressure 
measurment and, if possible, wedge pressure measure- 
ment of the hepatic veins are mandatory. This haemo- 
dynamic information, especially a pressure gradient across 
the retrohepatic IVC from the bifurcation distally up to 
the right atrium, should be obtained and considered when 
surgical therapy is planned. 
Of prime importance in the investigations is a liver 
biopsy to assess hepatocyte damage and the extent of 
fibrosis and cirrhosis. 
Management 
Untreated Budd-Chiari syndrome causes death in months 
or yearss4*xs; spontaneous resolution is rarely reported. 
Incidental case reports are available describing successful 
thrombolysis in the acute situation. Urokinase, strepto- 
kinase and recombinant tissue plasminogen activator are 
advocated as thrombolytic agentsx6-xx. It is difficult to 
understand why there should by any benefit from 
treatment with anticoagulants alone other than prevention 
of thrombus extensionxy, but this, in combination with 
diuretics, is all too often the first and sometimes the only 
step in the treatment of the syndrome. In general, surgery 
is almost always mandatory, its nature depending on the 
location of the outflow obstruction. Direct local treatment 
may be appropriate for a membrane or web in the IVC. A 
variety of shunt procedures are also available to which the 
transjugular intrahepatic portasystemic shunt (TIPS) has 
recently been added. Finally, liver transplantation may be 
the appropriate treatment for a few patients. 
Direct treatment 
As a web or membrane in the IVC as a cause of Budd- 
Chiari syndrome is more common in the East, the 
majority of series and case reports regarding direct 
treatment of this lesion are of Asian, Japanese and also 
South African origin. Percutaneous balloon angioplasty 
has been successful in selected cases, with a long-term 
follow-up of 6 years or more, sometimes after multiple 
proceduresy0-y2. Lifelong anticoagulation is advised in 
these patients. To prevent restenosis and occlusion, 
prophylactic use of intravascular metal stents, such as the 
Wallstent (Schneider, Bulach, Switzerland) and the 
Gianturco stent (William Cook, Bjzerverskov, Denmark) 
may be advi~able~ ' -~~.  Stenting and laser treatment of 
locally narrowed ostia of the hepatic veins has also been 
d e s ~ r i b e d ~ ~ , ~ ~ ;  an alternative treatment is transcardiac 
membranotomy or membrane e x c i s i ~ n ~ ~ ~ ~ ~ .  In more 
extensive obstruction involving stenosis of the IVC, 
cavoplasty with autologous pericardial patching under 
hypothermia and cardiopulmonary bypass may be carried 
. Obstruction of the IVC and hepatic veins has 
been corrected by resection of the part of the liver 
containing the terminal portions of the major hepatic 
veins and the diseased part of the IVC, followed by direct 
anastomosis to the right atrium. This procedure, first 
described by SenningIo4, allows hepatic venous blood to 
enter the right heart directly10s~106. 
out 100- 103 
Shunts 
The key concept of any shunt procedure is the conversion 
of one of the large splanchnic veins into an outflow tract 
Fig. 3 Different forms of shunt: 1, portacaval shunt; 2, mesocaval 
shunt; 3, mesoatrial shunt; 4, cavoatrial shunt 
of the congested liver and congested splanchnic area. 
Under these conditions the liver should be able to resume 
its normal function, with a reduction in portal 
hypertension preventing further complications. Different 
forms of shunting have been described in the treatment of 
Budd-Chiari syndrome, the choice depending on the 
patency of the IVC and the pressure gradient between the 
portal vein and vena cava. In Budd-Chiari syndrome 
confined to the hepatic veins, intraoperative angiography 
may show compression of the IVC by the caudate lobe, 
but no occlusion. In these circumstances the caval 
pressure will be in the typical range for patients with 
ascites, varying between 4 and 12 mmHg. In patients with 
caval obstruction caused by thrombosis or web formation, 
the IVC pressure rises easily to 20-23 mmHg. Portal or 
superior mesenteric vein pressures in Budd-Chiari 
syndrome107 are between 20 and 25 mmHg. If intra- 
operative manometric studies demonstrate pressure in the 
retrohepatic IVC equal to or greater than those in the 
portal vein, portacaval or mesocaval shunting will be 
ineffective and result in thrombosis, as a minimum 
pressure gradient of 10 mmHg is required to guarantee 
long-term shunt patency. In these circumstances a 
mesoatrial shunt is indicated (Fig. 3)10x,10y. 
Portacaval shunt 
If a shunt is indicated, the portacaval side-to-side 
construction is the procedure of choice only if the IVC 
pressure is substantially lower than the portal pressure. 
This shunt is performed preferably without interposition 
of a graft. Direct side-to-side anastomosis between the 
portal vein and the intrahepatic IVC is technically 
demanding, but it carries the highest patency rate of all 
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shunts108,1'0-112. Some authors regard a large caudate 
lobe as a contraindication or advise a partial resection, 
but Orloff and colleagues in their large series of more 
than 1400 cases have described a technique in which the 
direct side-to-side portacaval shunt remains free from 
compression by the caudate lobe; an internal jugular vein 
interposition graft is needed only in exceptional 
133. The hypertrophied caudate lobe may com- 
press the IVC hut, except in severe cases (more than 75 
per cent diameter compression), this narrowing seems to 
be of no haemodynamic relevance. Moreover, after a 
successful shunt procedure the caudate lobe may return to 
its previous volume. 
Mesocaval shunt 
The mesocaval interposition H shunt using homologous 
vena cava was first reported by Lord et and Read et 
al. ' I 5 .  In 1972 Drapanas and c011eagues~'~~"~ advocated 
use of a wide calibre (18-22-mm) Dacron (DuPont, 
Wilmington, Delaware, USA) prosthesis. The H shunt is 
simple and avoids hilar dissection; the portal vein and the 
infrahepatic suprarenal IVC are not compromised, 
allowing possible future liver t r an~p lan ta t ion~~ ,~ '~ .  
However, the price for this simplicity is a high rate of 
thrombotic complications, varying between 24 and 53 per 
cent' 19,120. Cameron and colleagues'21 introduced the 
mesocaval C shunt on the wider retropancreatic part of 
the superior mesenteric vein. This variation prevented 
thrombotic complications in a series of 30 patients. Today, 
the widest part, which is the preferred site for the 
anastomosis, of the superior mesenteric vein can easily 
be assessed by intraoperative ultrasonography. The 
introduction of externally reinforced polytetra- 
fluorethylene (PTFE) vascular grafts prompted the use of 
this material in mesocaval shunting, but long-term results 
are lacking. To overcome the thrombotic complications 
Bismuth and SherlockG4 prefer to use the internal jugular 
vein, with good results. Sixteen patients were treated with 
a venous mesocaval shunt, two of which thrombosed after 
technical complications relating to the shunt; both were 
successfully treated by thrombectomy. 
The survival rate after shunt procedures varies widely 
and is directly related to the pressure difference between 
the portal vein and IVC, and hence to the flow in the 
s h ~ n t ~ ~ ~ ~ ~ ~ ~ ~ ~ .  Once the patient has successfully recovered 
from surgery the prognosis and prospects of long-term 
survival are dictated by the underlying d i s e a ~ e l ~ ~ ? ~ ~ ~ .  
Mesoatrial shunt 
Bypass of the liver and IVC is indicated in patients in 
whom the IVC is (sub)totally occluded, especially in the 
case of coexisting obstruction of the hepatic veins for 
which angioplasty or membranotomy is neither indicated 
nor possiblelZs. Caval compression by the caudate lobe 
alone is seldom an indication for mesoatrial shunting, 
unless the difference in venous pressure in the mesenteric 
vein and IVC, measured directly during operation, is so 
small that the patency of a portacaval or mesocaval shunt 
is jeopardized. The haemodynamic consequences of the 
stenosis, as has previously been noted, should be 
quantified by cavography and pressure measure- 
m e n t ~ ' * ~ , ~ ~ ~ .  Since the first description by Cameron and 
Maddrey in 1978, different varieties of mesoatrial 
shunts have been suggestedIz8. The patency of these 
mesoatrial shunts varies between 75 and 100 per cent in 
some small series; the mean follow-up in all series is less 
than 2 yearslZ9-l3'. Others have had more discouraging 
results, with success rates of only 33-66 per centlog. Much 
attention has been paid to the technical details of the 
operation, and improved results have been claimed by 
using an external silicone rubber sleeve around a 16-mm 
externally reinforced PTFE prosthesis to prevent 
compression of the graft by the sternum'**. Warren and 
colleagues132 proposed a two-step procedure: first, 
decompression of the venous splanchnic bed by a 
mesoatrial shunt, resolving the swelling of the liver and 
the caudate lobe, followed by a second operation after 
several months with closure of the mesoatrial shunt and 
creation of a side-to-side portacaval shunt. Orloff et aL133 
reported unsatisfactory results in eight patients after 
mesoatrial shunting with 16-mm PTFE externally 
reinforced grafts. In five patients the graft occluded soon 
after operation, uniformly leading to death. After 
experimental work on cavoatrial shunting combined with 
side-to-side portacaval shunting, these authors' clinical 
results in five patients were improved, with no graft 
occlusion and no death. In this procedure the vascular 
graft receives venous blood from the obstructed 
splanchnic bed and from the obstructed IVC, leading to a 
high rate of blood flow through the graft, resulting in 
fewer thrombotic complications. 
Transjugular intrahepatic portaJystemic shunt 
The elegant TIPS procedure was recently introduced for 
relief of portal hypertension; it has been performed in a 
few patients with Budd-Chiari ~yndrome'~~- '~ ' .  The long- 
term results of TIPS insertion have not yet been evaluated 
and, especially in Budd-Chiari syndrome with (sub)total 
occlusion of the hepatic veins, cannulation is not always 
possible. Sometimes the shunt can be introduced through 
a large vein of the caudate lobe, but it is not clear 
whether positioning a TIPS through the only functioning 
part of the liver, i.e. the caudate lobe, does any good. A 
possible indication for a TIPS is acute bleeding, as it may 
allow a short-term stabilization of the patient who is 
awaiting definitive surgical treatment135,137. Thrombotic 
complications with a TIPS are common and only short- 
term follow-up studies are so far available. The 
indications for a TIPS are not completely clear and the 
procedure should be reserved for patients with acute 
fulminant Budd-Chiari syndrome to relieve variceal 
bleeding before liver transplantation. 
Liver transplantation 
The choice between shunt or liver transplantation for 
Budd-Chiari syndrome is affected by several factors, the 
most important of which is the estimated hepatic reserve. 
Salient features are the presence of encephalopathy, 
hypoalbuminaemia and hyperbilirubinaemia and, most 
significantly, the result of liver biopsy"'. The proportion 
of patients with Budd-Chiari syndrome receiving a liver 
transplant varies widely in different series. Three groups 
of patients with the syndrome requiring liver 
transplantation in preference to a shunt may be identified: 
those with Budd-Chiari syndrome presenting as fuiminant 
hepatic failure, those with end-stage chronic liver dkease 
at first presentation and those who rapidly deteriorate 
after a shunt p r o c e d ~ r e ~ ~ ~ ~ ~ ~ , ' ~ ~ .  Some studies of liver 
transplantation for Budd-Chiari syndrome contain a few 
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patients with fulminant hepatic but the 
clinical picture may be very impressive without irreversible 
loss of hepatic function, so no liver transplant should be 
done before adequate evaluation by hepatic biopsy. In 
patients presenting with end-stage chronic liver failure, 
the decision in favour of transplantation is more 
s t ra ightfor~ard '~~.  Even here, however, a liver biopsy 
showing extensive fibrosis and cirrhosis is mandatory 
before the surgical option of a shunt is d i s ~ a r d e d ' ~ ~ - ' ~ ~ .  
The survival rate after liver transplantation for Budd- 
Chiari syndrome varies from 45 to 80 per cent after 5 
years, but these figures are influenced by small numbers 
and better results in later series. All authors describe 
thrombotic complications in some patients, sooner or 
later, after transplantation, and so lifelong anticoagulant 
therapy is advised except in patients in whom a 
thrombogenic condition, such as antithrombin I11 
deficiency, is corrected by the liver transplantation. 
Depending on the underlying aetiology, liver 
transplantation for Budd-Chiari syndrome may be 
considered as palliative, requiring long-term adjuvant 
therapy, or as curative, with correction of a metabolic 
d e f e ~ t ' ~ ~ - ' ~ ~ .  
Conclusion 
Suspected Budd-Chiari syndrome should be confirmed by 
radiology, including venograms and pressure measure- 
ments in the IVC. Haematological or other underlying 
disorders should be evaluated. Based on the outcome of 
liver biopsy, three treatment pathways are possible. In 
exceptional cases liver biopsy may show neither necrosis 
nor fibrosis and this feature, combined with a mild clinical 
picture, may allow treatment by anticoagulation and 
administration of a diuretic. Re-evaluation should be 
thorough and frequent. In the majority of patients 
centrolobular necrosis is present without irreversible signs 
of fibrosis or cirrhosis. In these patients decompression by 
a shunt is the treatment of choice, the specific shunt 
depending on IVC haemodynamics. A small group of 
patients with severe fibrosis, or even cirrhosis, presenting 
with end-stage liver disease will benefit from liver 
transplantation, as do those with acute liver failure 
resulting from Budd-Chiari syndrome. 
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